{
  "docId": "019de071-f0b8-737f-9ff6-e8b6f7a1e960",
  "docSlug": "213575480fcc7466657230c6a0d87626",
  "documentTitle": "23andMe | Investor Day Presentation Deck | 78 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 42,
  "pageCount": 78,
  "prevPage": 41,
  "nextPage": 43,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-f0b8-737f-9ff6-e8b6f7a1e960/42",
  "deckHref": "/decks/019de071-f0b8-737f-9ff6-e8b6f7a1e960",
  "deckJsonHref": "/decks/019de071-f0b8-737f-9ff6-e8b6f7a1e960.json",
  "deckAnchorHref": "/decks/019de071-f0b8-737f-9ff6-e8b6f7a1e960#slide-42",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "23andMe’s I/O signature highlights potential targets with genetic evidence of importance\nCD200R1 is an immune checkpoint with a clearly defined I/O signature in three components of the pathway\nCD200R1 ligand is highly expressed in a subset of human cancers\n23ME ‘610 is a potent monoclonal antibody against CD200R1 that has the potential to restore T-cell killing of cancer cells\nThe Phase 1 study of 23ME ‘610 in patients with advanced solid malignancies has been initiated and the first patient was dosed in January 2022",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3df6963-6c18-466e-a65b-03ff6406ce32",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.15,
        "y": 0.05
      },
      "kind": "title",
      "text": "23ME '610 Targeting CD200R1: A Genetically-Validated Approach to Anti-Cancer Therapy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "420e7c51-d911-43fb-8d58-788037900d90",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 42,
      "from": 33,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "934e5ad9-c4e2-4bad-8ae5-f1cb9185ca0d",
      "evidence": "The presentation deck presents data and research findings on 23ME-00610, a novel immuno-oncology antibody targeting CD200R1",
      "position": 1,
      "objective": "Can 23andMe's immuno-oncology antibody targeting CD200R1 provide a quick win in cancer treatment?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}